OMZ delayed-release capsule
Ferron Par Pharmaceuticals
Ingredients in every delayed-release capsule
Each package contains
|ATC Level 1||A - Alimentary tract and metabolism|
|ATC Level 2||A02 - Drugs for Acid Related Disorders|
|ATC Level 3||A02A - Antacids|
18 YEARS OLD AND ABOVE
The recommended dose: 20 mg or 40 mg once daily swallowed whole with water.
• Patients with duodenal ulcer symptoms: treatment and healing may take 2 weeks. Patients who have not recovered within this initial treatment, usually require additional 2 weeks of therapy.
• Patients with peptic ulcers or erosive/ulcerative esophagitis reflux symptoms: treatment and healing may take 4 weeks. Patients who have not recovered usually require additional 4 weeks of treatment.
• Patients with refractory to other medications require 40 mg once daily and the healing usually attained within 4 weeks (for duodenal ulcer patients) or 8 weeks (for peptic ulcer or erosive/ulcerative esophagitis reflux).
• Patients with Zollinger-Ellison syndrome: initial dose is 20-160 mg once daily, the dose should be adjusted individually and treatment should be given as long as clinically indicated. Dose higher than 80 mg per day should be divided, twice daily.
Omeprazole capsule should be taken before meal.
The whole capsules should not be opened, chewed, or crushed and should be swallowed.
HEPATIC IMPAIRMENT, RENAL IMPAIRMENT
do not need special dose.
no dose adjustment is required for elderly patients.
there is no experience of the use of omeprazole in children.
– Short-term treatment of duodenal ulcers and which is unresponsive to H2 receptor antagonist drugs. (I p.3009, 3011; III p.3; IV p.O.17; VI p.2; VII; VIII p.4; IX p.13; X p.2210)
– Short-term treatment of peptic ulcers. (III p.3; IV p.O.17; V p.1; VI p.2; VII; VIII p.4; IX p.1; X p.2210)
– Treatment of erosive/ulcerative esophagitis reflux that has been diagnosed by endoscopy. (I p.3009, 3010; III p.3; IV p.O.17; V p.1, 2; VI p.2; VII; VIII p.4; IX p.13, 14; X p.2210)
– Long-term treatment of Zollinger-Ellison syndrome. (I p.3009, 3011; III p.3; IV p.O.17; V p.2; VI p.2; VII; VIII p.4; IX p.13)